Navigation Links
CorMedix, Inc. Granted Extension of NYSE-MKT Listing
Date:7/24/2014

iffer materially from projections or estimates due to a variety of important factors, including: the acceptance by the FDA of the protocol for the planned Phase 3 trial for Neutrolin; obtaining regulatory approvals to conduct clinical trials and to commercialize CorMedix's product candidates, including marketing of Neutrolin® in countries other than Germany; the risks associated with the launch of Neutrolin® in Europe and other markets; CorMedix's ability to maintain its listing on the NYSE MKT; the risks and uncertainties associated with CorMedix's ability to manage its limited cash resources; the outcome of clinical trials of CorMedix's product candidates and whether they demonstrate these candidates' safety and effectiveness; CorMedix's ability to enter into and maintain collaborations with third parties for its development and marketing programs; CorMedix's dependence on its collaborations and its license relationships; achieving milestones under CorMedix's collaborations; obtaining additional financing to support CorMedix's research and development and clinical activities and operations; CorMedix's dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers, sales and marketing organizations, and consultants; and protecting the intellectual property developed by or licensed to CorMedix. These and other risks are described in greater detail in CorMedix's filings with the SEC, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.


'/>"/>
SOURCE CorMedix Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
2. Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)
3. CE Mark Granted for Wound Spray Based on Sangui Patent
4. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
5. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
6. ERT Granted Patents on Clinical Trial Participant Compliance
7. Revolutionary Tetrapod Quantum Dot Synthesis US Patent Granted
8. Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
9. Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
10. Factor Bioscience Granted First U.S. Patent for RNA-Based Reprogramming Technology
11. Star Scientific Announces Patent Claims to Anatabine Citrate to be Granted by PTO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... India , August 28, 2015 ... by Product (Media, Sera, Cryogenic Storage Systems, Thawing Equipment, ... (Therapeutic, Regenerative Medicine, Clinical Trials), End User - Global ... Market is expected to reach USD 3,731.03 Million by ... a CAGR of 11.65% between 2015 and 2020. ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Wade McKenna, DO, announced today that the use of sterile, dehydrated amniotic tissue ... healing of an otherwise non-healing surgical knee wound. , The case involved a ...
(Date:8/27/2015)... 2015  Neogen Corporation (NASDAQ: NEOG ) announced ... United Kingdom -based Lab M Holdings, a ... diagnostic systems. Lab M was founded ... of microbial testing and diagnostic products for the global ... currently sells into more than 70 countries worldwide, and ...
(Date:8/27/2015)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced its ... Biorem,s complete second quarter financial statements and MD&A have been filed ... earnings per shareThree-months ended , Six -months endedJune 30 , June ... , 2014 Revenue , 4,709 , 2,459 ... 1,656 , 56 , 3,188 ...
Breaking Biology Technology:Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Neogen acquires U.K.-based Lab M Holdings 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3
... Ardea Biosciences,Inc. (Nasdaq: RDEA ) today announced ... non-nucleoside reverse transcriptase inhibitors (NNRTIs),at the 21st International ... of the Company,s mitogen-activated ERK kinase,(MEK) inhibitors, RDEA119 ... for Cancer Research (AACR) annual meeting., ...
... Calif., April 7, 2008 InterWest Partners,announced ... to the venture capital firm,s Advisory Committee: ... Leroy Hood, and,former FDA commissioner Dr. Mark ... experienced professional advisors, providing strategic guidance,to the ...
... CPHD ) will announce financial results for ... Thursday, May 1, 2008. The announcement will be,followed ... afternoon at 4:30 p.m.,Eastern Time., John Bishop, ... Financial Officer and Michael Myhre, Vice President,Corporate Controller, ...
Cached Biology Technology:Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences 2Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences 3Prestigious Scientific Leaders Join InterWest Advisory Committee 2Prestigious Scientific Leaders Join InterWest Advisory Committee 3Prestigious Scientific Leaders Join InterWest Advisory Committee 4Cepheid Schedules Teleconference and Webcast for First Quarter 2008 Results 2
(Date:8/18/2015)... N.J. , Aug. 18, 2015 /PRNewswire/ ... a key contributor to the Submission Content ... by IRISS, a non-profit forum. Dedicated to the ... provides a neutral platform for industry, vendors, ... share information and work towards a standard ...
(Date:8/17/2015)... OXFORD, Conn. , Aug. 17, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces its new sales campaign for Q4 2015. The ... winning marketing team consisting of Amplitude Marketing Group ( ... Amplitude Marketing Group is a leader in retail driven ...
(Date:8/12/2015)... , August 12, 2015 ... of mobile payment innovation and advanced biometrics technology is ... the way consumers rely on using their credit cards, ... reinventing the future for payment services led by companies ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ), ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... how diseases are diagnosednew research published in the May 2010 ... ) details a noninvasive ground-breaking tool that detects signs of ... using traditional methods. Even better, this tool promises to detect ... before any permanent damage can occur. Its use may well ...
... crawls onto your lips while you sleep, drawn by the ... your blood. And if that,s not insult enough, it promptly ... Now Jean-Paul Paluzzi, a PhD candidate in biology ... to prevent the insects from leaving their messy calling card ...
... A small piece of RNA appears to play a ... according to lung disease researchers at the University of Pittsburgh ... examine microRNAs in the disease, is available online in the ... MicroRNAs are short strands of genetic material that ...
Cached Biology News:New tool helps scientists 'see' molecular signals of eye disease before symptoms arise 2The kiss of death: Research targets lethal disease spread by insect that bites lips 2Pitt researchers discover big role for microRNA in lethal lung fibrosis 2
Request Info...
Request Info...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Detect and measure levels of mouse IgG3 antibody isotypes quickly and easily....
Biology Products: